129 related articles for article (PubMed ID: 12082622)
1. Loss of Stat5a delays mammary cancer progression in a mouse model.
Ren S; Cai HR; Li M; Furth PA
Oncogene; 2002 Jun; 21(27):4335-9. PubMed ID: 12082622
[TBL] [Abstract][Full Text] [Related]
2. Possible role of Stat5a in rat mammary gland carcinogenesis.
Shan L; Yu M; Clark BD; Snyderwine EG
Breast Cancer Res Treat; 2004 Dec; 88(3):263-72. PubMed ID: 15609129
[TBL] [Abstract][Full Text] [Related]
3. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
[TBL] [Abstract][Full Text] [Related]
4. Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis.
Humphreys RC; Hennighausen L
Cell Growth Differ; 1999 Oct; 10(10):685-94. PubMed ID: 10547072
[TBL] [Abstract][Full Text] [Related]
5. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis.
Iavnilovitch E; Groner B; Barash I
Mol Cancer Res; 2002 Nov; 1(1):32-47. PubMed ID: 12496367
[TBL] [Abstract][Full Text] [Related]
6. Functional rescue of Stat5a-null mammary tissue through the activation of compensating signals including Stat5b.
Liu X; Gallego MI; Smith GH; Robinson GW; Hennighausen L
Cell Growth Differ; 1998 Sep; 9(9):795-803. PubMed ID: 9751123
[TBL] [Abstract][Full Text] [Related]
7. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice.
Liu ML; Shibata MA; Von Lintig FC; Wang W; Cassenaer S; Boss GR; Green JE
Oncogene; 2001 Apr; 20(16):2044-9. PubMed ID: 11360188
[TBL] [Abstract][Full Text] [Related]
8. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth.
Vomachka AJ; Pratt SL; Lockefeer JA; Horseman ND
Oncogene; 2000 Feb; 19(8):1077-84. PubMed ID: 10713693
[TBL] [Abstract][Full Text] [Related]
9. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system.
Kazansky AV; Spencer DM; Greenberg NM
Cancer Res; 2003 Dec; 63(24):8757-62. PubMed ID: 14695191
[TBL] [Abstract][Full Text] [Related]
10. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
11. HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53.
Klein A; Guhl E; Tzeng YJ; Fuhrhop J; Levrero M; Graessmann M; Graessmann A
Oncogene; 2003 May; 22(19):2910-9. PubMed ID: 12771941
[TBL] [Abstract][Full Text] [Related]
12. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
13. Stat5a is essential for the proliferation and survival of murine mast cells.
Ikeda K; Nakajima H; Suzuki K; Watanabe N; Kagami S; Iwamoto I
Int Arch Allergy Immunol; 2005; 137 Suppl 1():45-50. PubMed ID: 15947484
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells.
Yamashita H; Iwase H; Toyama T; Fujii Y
Oncogene; 2003 Mar; 22(11):1638-52. PubMed ID: 12642867
[TBL] [Abstract][Full Text] [Related]
15. Constitutive activation of Stat5b contributes to carcinogenesis in vivo.
Xi S; Zhang Q; Gooding WE; Smithgall TE; Grandis JR
Cancer Res; 2003 Oct; 63(20):6763-71. PubMed ID: 14583472
[TBL] [Abstract][Full Text] [Related]
16. Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice.
Zhang M; Shi Y; Magit D; Furth PA; Sager R
Oncogene; 2000 Dec; 19(52):6053-8. PubMed ID: 11146557
[TBL] [Abstract][Full Text] [Related]
17. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
18. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
19. Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model.
Furth PA; Bar-Peled U; Li M; Lewis A; Laucirica R; Jäger R; Weiher H; Russell RG
Oncogene; 1999 Nov; 18(47):6589-96. PubMed ID: 10597263
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice.
Murphy KL; Kittrell FS; Gay JP; Jäger R; Medina D; Rosen JM
Oncogene; 1999 Nov; 18(47):6597-604. PubMed ID: 10597264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
